Moghaddas Azadeh, Dianatkhah Mehrnoush, Ghaffari Saba, Ghaeli Padideh
Department of Clinical Pharmacy, Faculty of Pharmacy, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Psychiatry. 2017 Apr;12(2):142-146.
Management of borderline personality disorder (BPD) is a difficult challenge due to the complex features of this disorder. This article reviews the use of naltrexone in the treatment of BPD. Published articles and clinical trials were searched in Google Scholar, MedLine, ELSEVIER, and Cochrane database of systematic reviews abstracts in English language between 1990 and 2017. Naltrexone (NTX), a nonspecific competitive opiate antagonist, has been noted to be helpful in controlling self-injurious behavior (SIB) and dissociative symptoms in patients with BPD. Further studies should be conducted on the effects of naltrexone to confirm the role of this medication in the treatment of BPD.
由于边缘型人格障碍（BPD）具有复杂的特征，对其进行管理是一项艰巨的挑战。本文综述了纳曲酮在BPD治疗中的应用。在1990年至2017年期间，我们在谷歌学术、医学在线数据库、爱思唯尔数据库以及考克兰系统评价摘要数据库中搜索了已发表的文章和临床试验，检索语言限定为英文。纳曲酮（NTX）是一种非特异性竞争性阿片拮抗剂，已被证实有助于控制BPD患者的自我伤害行为（SIB）和解离症状。应进一步研究纳曲酮的作用，以确认该药物在BPD治疗中的地位。
